Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xspray Pharma, a product development firm with various product candidates in clinical development, has announced positive data from a clinical bioequivalence study with its lead product candidate HyNap-Dasa.
Image: Xspray Pharma has reported positive clinical data for HyNap-Dasa product candidate. Photo: courtesy of Jan Friml / FreeImages.
Subscribe to our email newsletter
The study results confirmed its primary aim to show bioequivalence of an optimized formulation of HyNap-Dasa compared to Sprycel.
The data will be instrumental in the design of the planned registration study for an ANDA application.
The completed clinical Phase I study examined HyNap-Dasa’s bioavailability compared to the dasatinib cancer drug, currently marketed as Sprycel for the treatment of chronic myeloid leukemia (CML). In the study, bioavailability of two different tablet formulations of HyNap-Dasa was tested in comparison with Sprycel tablets in 16 healthy subjects.
The results are very positive and confirm the validity of Xspray’s patented formulation technology. The planned studies required to take HyNap-Dasa to final registration studies will now be performed as planned. The results also strengthen the potential for additional product candidates in the pipeline being developed with the same technology to reach the market.
Xspray Pharma CEO Per Andersson said: “I am happy to see that the data so strongly confirm our technology. The outcome of this study represents an important milestone for Xspray Pharma as it means that we now can initiate the preparation of the pivotal phase of the clinical program, taking us closer to a commercial launch of HyNap-Dasa.
“Furthermore, the results pave the way also for additional product candidates in our pipeline. It signifies a new and important step in our development as a company.”
The study compared the pharmacokinetic parameters Cmax and AUC for the originator product Sprycel® and two different HyNap tablet formulations of dasatinib. Sixteen healthy volunteers received single doses of each product in a cross-over design.
Although this study was not powered to demonstrate formal bioequivalence, an analysis of preliminary data indicate that bioequivalence with Sprycel was achieved for one of the HyNap formulations. The results demonstrate a high likelihood that formal bioequivalence will be achieved in an adequately powered study.
Xspray Pharma AB (publ) is a product development company with several product candidates in clinical development. Xspray uses its innovative patented RightSize technology to develop improved as well as generic versions of marketed cancer drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer.
Source: Company Press Release
